The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.
This funding boost will help Altamira progress their innovative pipeline while also supporting their ongoing divestment of legacy assets in allergology, viral infections, and inner ear disorders.
Some results have been hidden because they may be inaccessible to you